(S (PP (IN With) (NP (NP (DT the) (JJ fast) (NN development)) (PP (IN of) (NP (NP (NNP COVID) (HYPH -) (CD 19)) (PP (IN into) (NP (DT a) (JJ global) (NN pandemic))))))) (, ,) (NP (NP (NNS scientists)) (PP (IN around) (NP (DT the) (NN globe)))) (VP (VBP are) (ADVP (RB desperately)) (VP (VBG searching) (PP (IN for) (NP (JJ effective) (JJ antiviral) (JJ therapeutic) (NNS agents))))) (. .))
(S (S (VP (VBG Bridging) (NP (NML (NNS systems) (NN biology) (CC and) (NN drug)) (NN discovery)))) (, ,) (NP (PRP we)) (VP (VBP propose) (NP (DT a) (JJ deep) (NN learning) (NN framework)) (PP (IN for) (NP (NP (JJ conditional) (ADJP (FW de) (FW novo)) (NN design)) (PP (IN of) (NP (NP (JJ antiviral) (NN candidate) (NNS drugs)) (VP (VBN tailored) (PP (IN against) (NP (VBN given) (NN protein) (NNS targets))))))))) (. .))
(S (ADVP (RB First)) (, ,) (NP (PRP we)) (VP (VBP train) (NP (NP (DT a) (JJ multimodal) (NN ligand)) (: --) (NP (NP (NML (NN protein) (NN binding)) (NN affinity) (NN model)) (PP (IN on) (S (VP (VBG predicting) (NP (NP (NNS affinities)) (PP (IN of) (NP (JJ antiviral) (NNS compounds)))) (S (VP (TO to) (VP (VB target) (NP (NN proteins) (CC and) (NN couple)) (S (NP (NP (DT this) (NN model)) (PP (IN with) (NP (JJ pharmacological) (NN toxicity) (NNS predictors)))))))))))))) (. .))
(S (S (VP (VBG Exploiting) (NP (NP (DT this) (ADJP (JJ multi-objective) (PP (IN as) (NP (DT a) (NN reward)))) (NN function)) (PP (IN of) (NP (NP (DT a) (JJ conditional) (JJ molecular) (NN generator)) (-LRB- -LRB-) (VP (VBG consisting) (PP (IN of) (NP (CD two) (NNS VAEs)))) (-RRB- -RRB-)))))) (, ,) (NP (PRP we)) (VP (VBP showcase) (NP (NP (DT a) (NN framework)) (SBAR (WHNP (WDT that)) (S (VP (VBZ navigates) (NP (DT the) (NN chemical) (NN space)) (PP (IN toward) (NP (NP (NNS regions)) (PP (IN with) (NP (JJR more) (JJ antiviral) (NNS molecules)))))))))) (. .))
(S (ADVP (RB Specifically)) (, ,) (NP (PRP we)) (VP (VBP explore) (NP (NP (DT a) (JJ challenging) (NN setting)) (PP (IN of) (S (VP (VBG generating) (NP (NP (NNS ligands)) (PP (IN against) (NP (JJ unseen) (NN protein) (NNS targets)))) (PP (IN by) (S (VP (VBG performing) (NP (DT a) (NML (NML (NN leave) (HYPH -) (CD one)) (HYPH -) (PP (IN out) (HYPH -) (NP (NN cross-validation))))) (PP (IN on) (NP (CD 41))) (SBAR (S (NP (NNP SARS) (HYPH -) (NNP CoV)) (VP (VBD -2-related) (NP (NN target) (NN proteins))))))))))))) (. .))
(S (S (VP (VBG Using) (NP (JJ deep) (NN RL)))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN demonstrated) (SBAR (IN that) (S (PP (IN in) (NP (QP (CD 35) (IN out) (IN of) (CD 41)) (NNS cases))) (, ,) (NP (DT the) (NN generation)) (VP (VBZ is) (ADJP (JJ biased) (PP (IN towards) (NP (VBG sampling) (NML (JJR more) (NN binding)) (NNS ligands))))))) (, ,) (PP (IN with) (NP (NP (DT an) (JJ average) (NN increase)) (PP (IN of) (NP (NP (CD 83) (NN %)) (VP (VBG comparing) (PP (IN to) (NP (DT an) (JJ unbiased) (NNP VAE)))))))))) (. .))
(S (NP (PRP We)) (VP (VP (VBP present) (NP (DT a) (NN case) (HYPH -) (NN study)) (PP (IN on) (NP (DT a) (JJ potential) (NML (NN Envelope) (HYPH -) (NN protein)) (NN inhibitor)))) (CC and) (VP (VB perform) (NP (NP (DT a) (JJ synthetic) (NN accessibility) (NN assessment)) (PP (IN of) (NP (NP (DT the) (JJS best)) (VP (VBN generated) (SBAR (S (NP (NNS molecules)) (VP (VBZ is) (VP (VBN performed) (SBAR (IN that) (S (VP (VBZ resembles) (NP (NP (DT a) (JJ viable) (NN roadmap)) (PP (IN towards) (NP (DT a) (JJ rapid)))) (PP (IN in) (HYPH -) (NP (NP (ADVP (FW vitro)) (NN evaluation)) (PP (IN of) (NP (JJ potential) (NNP SARS) (HYPH -) (NML (NNP CoV) (HYPH -) (CD 2)) (NNS inhibitors)))))))))))))))))) (. .))
